ASH 2018 | AMG 420 BiTE for R/R multiple myeloma

Thierry Facon

The AMG 420 bi-specific T-cell engager (BiTE) therapy which targets the anti–B-cell maturation antigen (BCMA) is now being tested in relapsed/refractory multiple myeloma (MM). Here, Thierry Facon, MD, of Lille University Hospital, Lille, France, also discusses the latest data from the Phase I dose-escalation study (NCT02514239) assessing the safety, tolerability and anti‑tumor activity of AMG 420, a CD3 BiTE. Dr Facon presented the data at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA,

Share this video